摘要
[目的]观察冻干重组人脑利钠肽（新活素）治疗急性心力衰竭患者的临床疗效。[方法]选取210例急性心衰患者，分为对照组90例，观察组120例，对照组采用常规治疗，观察组在常规治疗基础上加用新活素，观察两组治疗前后的临床症状、左室射血分数（LVEF）及血浆N-末端脑钠肽前体（NT-proBNP）水平的变化。[结果]①观察组治疗后各项指标改善均优于对照组[总有效93．3％ vs 73．3％， P ＜0．05；显效60．0％ vs 35．6％，P ＜0．05；治疗后 LVEF （55±12）％ vs （52±11）％，P ＜0．05；NT-proBNP水平（1050．6±568．1） pg/mL vs （2100．8±789．2） pg/mL ，P＜0．05]；②观察组中，新活素治疗对急性心衰患者较慢性心衰加重患者的效果更明显[总有效97．1％ vs88．0％，P ＜0．05；显效70．0％ vs46．0％，P ＜0．05；治疗后LVEF （58±11）％ vs （48±8）％，P ＜0．05；治疗后 NT-proBNP水平（780．9±365．7） pg/mL vs （1866±1075．8） pg/mL ，P ＜0．05]。[结论]新活素显著改善急性心衰患者的临床症状和心功能，且对急性发作心衰患者更有效。
[Objective]To observe clinical efficacy of lyophilized recombinant human brain natriuretic pep-tide（rhBNP） for the treatment of patients with acute heart failure .[Methods]A total of 210 patients who suf-fered from acute heart failure were chosen and divided into control group （ n=90） and observation group（ n=120） .The control group was given traditional treatment ,while the observation group was given rhBNP in ad-dition to traditional treatment .The changes of clinical symptoms ,left ventricular ejection fraction （LVEF） and plasma NT-proBNP before and after treatment were observed .[Results]After treatment ,the improvement of all indexes in observation group was better than control group （total effective rate was 93 .3% and 73 .3% ,P〈0 .05 ,excellent efficiency was 60 .0% and 35 .6% ,P〈0 .05 ,LVEF after treatment was 55 ± 12% and 52 ± 11% ,P 〈0 .05 ,NT-proBNP after treatment was 1050 .6 ± 568 .1pg/mL and 2100 .8 ± 789 .2pg/mL ,P 〈0 .05） .In the observation group ,the efficacy in patients with acute heart failure was more obvious than that in patients with aggravated chronic heart failure （total effective rate was 97 .1% and 88 .0% ,P〈0 .05 ,excellent efficiency was 70 .0% and 46 .0% ,P 〈0 .05 ,LVEF after treatment was 58 ± 11% and 48 ± 8% ,P 〈0 .05 , NT-proBNP after treatment was 780 .9 ± 365 .7pg/mL and 1866 ± 1075 .8pg/mL ,P〈0 .05） .[Conclusion]The rhBNP can significantly improve clinical symptoms and cardiac function in patients with acute heart failure ,es-pecially for patients with acute onset heart failure .
出处
《医学临床研究》
CAS
2014年第1期146-148,共3页
Journal of Clinical Research
